Since the early 2000s, the popularity of zebrafish in *in vivo* drug screening has shown a substantial increase. The zebrafish has become an important screening tool covering a wide range of tissue-specific pathologies and diseases/disorders. Nowadays, phenotype-based screening is favoured over target-based screening approaches, because it can identify active drugs/small molecules in the absence of a known target or suspected mechanism of action. Phenotypic screens can identify not only compounds with a positive effect, but also compounds with off-target effect. Another advantage of whole-organisms screening is the bioavailability of compounds, and the fact that in vivo experiments will allow the normal metabolismization of these compounds by the living organisms. Overall, this type of approach has boosted the discovery of higher quality compounds compared to in vitro target-based screens (Zhang and Peterson, 2019).

**Advantages of zebrafish for drug screening:**

All phenotypic screens carried out in cell culture are limited to cell-autonomous phenotypes and to end points that can be easily observed in culture systems. Hence, the necessity becomes evident to have a model that shows complex biological processes and a system of internal organs that potentially metabolises compounds—an intact, living organism. Such an organism is the zebrafish (*Danio rerio*), a small tropical fish that is native to Asia. Zebrafish share a high gene homology with humans, and many of the genes associated with various human diseases have a zebrafish counterpart. Because of this high genetic homology and human-like tissues and organs, zebrafish can be used to study the mechanisms of various human diseases. Zebrafish are very easy to handle, and the cost of maintenance is low compared to other medium-size models, like rodents. The embryos and larvae are optically transparent making it easy to follow internal organ development after any genetic manipulation (CRISP/Cas9, morpholino injections) or pharmacological treatment by non-invasive imaging techniques. Nowadays the availability of various transgenic reporter lines makes the analysis of cell/structure of interest very easy. Zebrafish produce a large number of offspring (200–300), which in turn can be translated into a high number of compounds/small molecules being tested in parallel. Thus, large clutch size and ease of drug administration (direct administration in water) make zebrafish an excellent tool for automated/semi-automated medium-to-high-throughput drug screening.

**The chondrolectin mutant line, a model for motor neuron diseases:**

The generic term “motor neuron diseases” refers to a clinically heterogenous group of developmental and neurodegenerative disorders, characterized by the progressive loss of upper motor neurons, lower motor neurons or both, associated with muscular atrophy or spasticity. Numerous zebrafish lines are now available to study various aspects of the neurodegenerative disorders (mutants, gain-and-loss-of-function models, overexpression models) (Wang et al., 2021). One of our main line of research for our group is compound screen in zebrafish model of motor neuron disease, like spinal muscular atrophy (SMA). SMA is characterized by degeneration of lower motor neurons due to a deletion in survival motor neuron 1 gene (SMN1), which leads to downstream dysregulation of various genes (142 genes). One of the earliest dysregulated genes is chondrolectin (chodl) (Zhang et al., 2008; Bäumer et al., 2009), a type-I transmembrane C-type lectin protein expressed by zebrafish motor neurons (Zhong et al., 2012) and fast motor neurons in mice (Enjin et al., 2010). Interestingly, overexpression of chodl in a zebrafish SMA depletion model is able to partially rescue the motor neuron axonal patterning defects (truncated axons, excessive branching, missing axons) caused by SMN depletion (Sleigh et al., 2014). By generating a chodl mutant line we showed in an earlier study that chondrolectin is important in neuromuscular synapse differentiation in zebrafish and mice, and in synapse-dependent motor axon growth in zebrafish (Oprişoreanu et al., 2019). The chodl mutant line displays stalled CaP (caudal primary) motor axons at the horizontal myoseptum and various synaptic defects (Oprişoreanu et al., 2019), suggesting a role of chodl in synapse maturation and stabilization (Figure 1). Thus, synapse destabilization observed in the early phase of SMA might correlate with chondrolectin dysregulation at same stage.

**VAST Biolmager screening platform, a boost for drug discovery for neurodegenerative disorders:**

The necessity of screening more libraries/compounds in a short period of time has grown over the years. In this respect, the VAST technology has proven to be a big asset, because this automated/semi-automated system can load/unload the zebrafish embryos or larvae and image them. The speed and accuracy of the VAST Biolmager platform outstands the “classical work”, where 8 to 10 hours would be spent to manually perform all the necessary tasks (mounting, imaging) only to screen 20 compounds, compared to just 4 hours using the VAST screening platform. In the past, the VAST Biolmager platform has been used to screen older embryos and larvae [48 hours post-fertilization (hpf), 72 hpf and 96 hpf] (Early et al., 2018; Ansar et al., 2019). By refining several parameters for loading/unloading, detection and imaging on the VAST Biolmager, we were able to screen younger (28–30 hpf) and less pigmented zebrafish embryos than previously possible. Thus, biological processes taking place in earlier developmental stages can now be assessed much quicker. Nowadays, commercially available libraries containing hundreds of small molecules (biologically active compounds with low molecular weight), can be tested in a short period of time (months). For example, in a couple of months, we have tested over 900 compounds on our chodl mutant (around 50 screening days/1 person).

**The road to the ideal quantification:**

To narrow down a list of compounds (“hits”), likely influencing your process of interest, can be a difficult task, making it challenging to find the perfect way to analyse the results. It takes time to identify the best parameters to be measured and quantified. In our case, the phenotype of the chodl mutant line has the advantage that more than 75% of the CaP motor axons are stalled at the horizontal myoseptum (Figure 1). Thus, we developed a two-stage approach to quantify the results. In the first step, we scored the number of CaP motor neurons that passed...
the horizontal myoseptum, and in the second step we quantified the total axon length of the CaP motor axons. This second parameter is necessary because although the chodl phenotype can be rescued by various compound/small molecules, the total length of CaP motor axons can be variable such that more robust effects can be detected by axon length quantification, rather than scoring. The length of CaP motor axons is relevant for the entire musculature innervation. Out of 982 compounds screened, 12 induced an increase in the number of motor axons that grow beyond the horizontal myoseptum, and out of these 12 only 4 compounds induced a statistically significant increase in the total axon length. Our hit rates are similar to other screens in zebrafish (1.22% and 0.40%). This clearly indicates that our approach is valid and by having a 2-step quantification approach we can reduce the list of potential candidates. In this way, we also improved the quality/relevance of the candidates carried further. Because our aim was to find compounds that stabilized synapses, we introduced a 3rd parameter to be analyzed, which was analyses of synapse integrity/maturity. We showed that only 2 compounds were able to rescue some of the synaptic defects of the chodl mutant.

Introducing a 2nd model in the screening paradigm: Many chemical screens usually rely on one single model to identify relevant compounds for a certain disease/disorder, an approach that can be limited in biological relevance. There is the need to test the compounds on several similar or related models (mutant lines) to fully understand its effectiveness. A secondary related model can offer a different perspective and shed some light in the possible mechanisms of action of the compounds. Because chodl is a key factor downstream of SMN pathway and is linked to spinal muscular atrophy, the UBA1 model of SMA was chosen as a secondary model in our screening paradigm. The UBA1 model is a chemical-induced model, in which UBEI-41 inhibitor blocks the activity of UBA1 enzyme (ubiquitin-like modifier-activating enzyme 1). Compared to the chodl mutant the UBA1 model displays an array of axonal abnormalities from truncated or missing axons to severe branching. We have shown that the top candidate from the screen on chodl mutant fish, dipyridamole, was able to partially rescue the axonal defects in the UBA1 model. Hence, accumulating evidence suggest that dipyridamole has neuroprotective properties, which could include synapse protection, as well.

In conclusion, the VAST Biolmager can be used for a variety of zebrafish models from neural to non-neural in vivo models, providing those cells of interest are transgenically labeled. Furthermore, choosing a two-model system screen over one-model can be beneficial and strengthen the robustness of the results.

Ana-Maria Oprisoreanu*
Center for Regenerative Therapies Dresden (CRTD),
TU Dresden, Dresden, Germany
*Correspondence to: Ana-Maria Oprisoreanu, PhD, ana-maria.oprisoreanu@tu-dresden.de. https://orcid.org/0000-0002-9409-0830
(Ana-Maria Oprisoreanu)

Date of submission: July 29, 2021
Date of decision: August 31, 2021
Date of acceptance: September 8, 2021
Date of web publication: April 1, 2022

https://doi.org/10.4103/1673-5374.335795

How to cite this article: Oprisoreanu AM (2022) Perspective on automated in vivo drug screening using the chodl mutant zebrafish line. Neural Regen Res 17(11):2437-2438.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Ansar M, Ullah F, Paracha SA, Adams DJ, Lai A, Pais I, Iwazwiekiewicz J, Millan F, Sarwar MT, Agha Z, Shah SF, Qaisar AA, Falconnet E, Zoete V, Ranza E, Makrythanasis P, Santoni FA, Ahmed J, Katsanis N, Walsh C, et al. (2019) Bi-allelic variants in DYNC1I2 cause syndromic microcephaly with intellectual disability, cerebral malformations, and dysmorphic facial features. Am J Hum Genet 104:1073-1087.

Bäumer D, Lee S, Nicholson G, Davies JL, Parkinson NJ, Murray LM, Gillingwater TH, Anそre O, Davies KE, Talbot K (2009) Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genetics 5:e1000773.

Early JJ, Cole KL, Williamson JM, Swire M, Kamadurai H, Muskavitch M, Lyons DA (2018) An automated high-resolution in vivo screen in zebrafish to identify chemical regulators of myelination. Elife 7:e35136.

Enjin A, Rabe N, Nakanishi ST, Vallett S, Gezelius H, Memic F, Lind M, Hjalt T, Tourtellotte WG, Bruder C, Eichele G, Whelan PJ, Kullander K (2010) Identification of novel spinal cholinergic genetic subtypes disclose chodl and Ptx2 as markers for fast motor neurons and partitioning cells. J Comp Neurol 518:2284-2304.

Oprisoreanu AM, Smith HL, Aray S, Webster R, Zhong Z, Eaton-Hart C, Wehner D, Cardozo MJ, Becker T, Talbot K, Becker CG (2019) Interaction of axonal chondrolectin with collagen XIXa is necessary for precise neuromuscular junction formation. Cell Rep 29:1082-1098.

Oprisoreanu AM, Smith HL, Krix S, Chatyow H, Carragher NO, Gillingwater TH, Becker CG, Becker T (2021) Automated in vivo drug screen in zebrafish identifies synapstabilising drugs with relevance to spinal muscular atrophy. Dis Model Mech 14:dmm047761.

Sleigh JN, Barreiro-Iglesias A, Oliver PL, Biba A, Becker T, Davies KE, Becker CG, Talbot K (2014) Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Hum Mol Genet 23:855-869.

Wang X, Zhang JB, He KJ, Wang F, Liu CF (2021) Advances of zebrafish in neurodegenerative disease: from models to drug discovery. Front Pharmacol 12:713963.

Zhong T, Peterson RT (2019) Zebrafish as a platform for drug screening, the Zebrafish in biomedical research: biology, husbandry, diseases, and research applications. San Diego: Elsevier.

Zhang Z, Lotti F, Dittmar K, Younts I, Wan L, Kasim M, Dreyfuss G (2008) SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133:585-600.

Zhong Z, Onnacht D, Reimer MM, Barch I, Becker T, Becker CG (2012) Chondrolectin mediates growth cone interactions of motor axons with an intermediate target. J Neurosci 32:4426-4439.

C-Editors: Zhao M, Liu WJ, Li YY; T-Editor: Jia Y